5-cyano-1,1-dimethyl-2,3-epoxyindane | 124369-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 5-cyano-1,1-dimethyl-2,3-epoxyindane
• 英文别名: 1,1-dimethyl-2,3-epoxy-5-cyanoindane；6,6-dimethyl-1a,6a-dihydroindeno[1,2-b]oxirene-3-carbonitrile
• CAS: 124369-51-3
• 化学式: C₁₂H₁₁NO
• 分子量: 185.225
• InChiKey: YAJUCCJTUDCORR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  36.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-cyano-1,1-dimethyl-2,3-epoxyindane 、 哌啶酮 以5%的产率得到
  参考文献：
  名称：

  BUCKLE, DEREK R.;ARCH, JONATHAN R. S.;EDGE, COLIN;FOSTER, KEITH A.;HOUGE-+, J. MED. CHEM., 34,(1991) N, C. 919-926

  摘要：

  DOI：
• 作为产物：
  描述：

  1,1-dimethyl-5-cyanoindan-3-one 在 钾硼氢 、 对甲苯磺酸 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 65.0h， 生成 5-cyano-1,1-dimethyl-2,3-epoxyindane
  参考文献：
  名称：

  一系列新的钾通道激活剂：3-酰胺基-1,1-二甲基茚满-2-醇的合成和平滑肌松弛活性。

  摘要：

  描述了一系列新的平滑肌松弛剂的合成，所述平滑肌松弛剂已显示出通过钾通道的开放或激活起作用。已经评估了化合物抑制豚鼠分离的气管中自发音的能力，并讨论了结构-活性关系。一种化合物，特别是1,1-二甲基-5-硝基-3-（2-吡啶-1-基）茚满-2-醇（16）被确定为体外气道平滑肌的有效缓和剂，IC50 =攻击前30-45分钟口服0.15 microM，可显着抑制清醒豚鼠的组胺诱导的呼吸困难。

  DOI：

  10.1021/jm00107a008

文献信息

• Indane derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0321175A1

  公开（公告）日：1989-06-21

  A compound of formula (I): or, where appropriate, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof wherein A represents >C=X, wherein X represents oxygen or sulphur, or A represents a bond; Y represents N or N⁺-O⁻ or a moiety CR₈, and the other substituents are defined as in claim 1; a process for the preparation of such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound and composition in medicine.

  一种具有化学式（I）的化合物：或适当时，其药学上可接受的盐，或其药学上可接受的溶剂化合物其中A代表>C=X，其中X代表氧或硫，或A代表键；Y代表N或N⁺-O⁻或一个基团CR₈，其它取代基的定义如权利要求1中；一种制备这种化合物的方法，包括这种化合物的药物组合物以及在医学中使用这种化合物和组合物。
• Certain 1,2,4-triazole(oxy or amino)benzopyran derivatives having
  申请人：Beecham Group p.l.c.

  公开号：US05232938A1

  公开（公告）日：1993-08-03

  Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein a, b, J, Y and R.sub.2 -R.sub.8 are as defined herein are potassium channel activators, a process for their preparation and their pharmaceutical use.

  化合物I的公式及其药学上可接受的盐：其中a，b，J，Y和R2-R8的定义如本文所述，是钾通道激活剂，其制备方法及其药学用途。
• Guanidino-substituted benzopyrans and their use as pharmaceuticals
  申请人：Beecham Group p.l.c.

  公开号：US05053427A1

  公开（公告）日：1991-10-01

  Compounds of formula (I) and pharmaceutically acceptable salts thereof: ##STR1## wherein a and b together form an --O-- or --CH.sub.2 -- linkage or a bond; either Y is N and R.sub.2 is hydrogen; or Y is C-R.sub.1 wherein either one of R.sub.1 and R.sub.2 is hydrogen and the other is nitro, cyano, halo, CF.sub.3, formyl, aldoxime, CF.sub.3 O, NO.sub.2 --CH.dbd.CH--, NC--CH.dbd.CH--; a group R.sub.x X-- wherein R.sub.x and C.sub.1-6 alkyl, aryl or heteroaryl either of which may be optionally substituted by one, two or three of C.sub.1-4 alkyl, C.sub.1-4 alkoxy, nitro, halo, CF.sub.3 and cyano; and X is C.dbd.O, O.C.dbd.O, C.dbd.0.0, CHOH, SO, SO.sub.2, 0.SO, 0.SO.sub.2, CONH, 0.CONH, C.dbd.S, 0.C.dbd.S, C.dbd.S.0, CH.SH, SONH, SO.sub.2 NH, 0.SONH, 0.SO.sub.2 NH, CO--CH.dbd.CH, C.dbd.NHOH, C.dbd.NNH.sub.2 ; or a group R.sub.y R.sub.z NZ-- wherein R.sub.y and R.sub.z are independently hydrogen or C.sub.1-6 alkyl and Z is C.dbd.O, SO or SO.sub.2 ; or R.sub.1 is a C.sub.3-8 cycloalkyl group or a C.sub.1-6 alkyl group optionally substituted by a group which is hydroxy, C.sub.1-6 alkoxy, amino optionally substituted by one or two C.sub.1-6 alkyl groups, C.sub.1-7 alkanoylamino, C.sub.3-8 cycloalkyloxy or C.sub.3-8 cycloalkylamino; and R.sub.2 is hydrogen; or one of R.sub.1 and R.sub.2 is nitro, cyano or C.sub.1-3 alkylcarbonyl and the other is a different group selected from nitro, cyano, halo, C.sub.1-3 alkylcarbonyl, methoxy or amino optionally substituted by one or two C.sub.1-6 alkyl or by C.sub.2-7 alkanoyl; either one of R.sub.3 and R.sub.4 is hydrogen or C.sub.1-4 alkyl and the other is C.sub.1-4 alkyl; or R.sub.3 and R.sub.4 together are C.sub.2-5 polymethylene; either R.sub.5 is hydrogen, hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy; and R.sub.6 is hydrogen; or R.sub.5 and R.sub.6 together are a bond; either R.sub.7 is hydrogen, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.2-6 alkenyl or C.sub.2-6 alkynyl; and R.sub.8 is hydrogen or C.sub.1-6 alkyl; or R.sub.7 and R.sub.8 together are C.sub.2-4 polymethylene; R.sub.9 is CN, NO.sub.2, COR.sub.10 or SO.sub.2 R.sub.10 wherein R.sub.10 is C.sub.1-3 alkyl, NH.sub.2, NH(C.sub.1-3 alkyl), CF.sub.3 or phenyl optionally substituted as defined for R.sub.x ; and the R.sub.8 N(NR.sub.9)NHR.sub.7 moiety is trans to the R.sub.5 group when R.sub.5 is hydroxy, C.sub.1-6 alkoxy or C.sub.1-7 acyloxy; having antihypertensive and/or bronchodilator activity, processes for their preparation and their use as pharmaceuticals.

  化合物I的公式及其药用可接受的盐：其中a和b共同形成一个-O-或-CH.sub.2-连接或键合; Y为N且R.sub.2为氢; 或Y为C-R.sub.1，其中R.sub.1和R.sub.2中的任意一个为氢，另一个为硝基、氰基、卤素、CF.sub.3、甲酰基、醛肟、CF.sub.3O、NO.sub.2-CH.dbd.CH-、NC-CH.dbd.CH-; 一个R.sub.x X-基团，其中R.sub.x和C.sub.1-6烷基、芳基或杂环芳基，其中任意一个可选地被一个、两个或三个C.sub.1-4烷基、C.sub.1-4烷氧基、硝基、卤素、CF.sub.3和氰基取代; X为C.dbd.O、O.C.dbd.O、C.dbd.0.0、CHOH、SO、SO.sub.2、0.SO、0.SO.sub.2、CONH、0.CONH、C.dbd.S、0.C.dbd.S、C.dbd.S.0、CH.SH、SONH、SO.sub.2NH、0.SONH、0.SO.sub.2NH、CO-CH.dbd.CH、C.dbd.NHOH、C.dbd.NNH.sub.2; 或一个R.sub.yR.sub.zNZ-基团，其中R.sub.y和R.sub.z独立地为氢或C.sub.1-6烷基，Z为C.dbd.O、SO或SO.sub.2; 或R.sub.1为C.sub.3-8环烷基或C.sub.1-6烷基，可选地被一个羟基、C.sub.1-6烷氧基、氨基、C.sub.1-7酰胺基、C.sub.3-8环烷氧基或C.sub.3-8环烷基氨基取代; R.sub.2为氢; 或R.sub.1和R.sub.2中的一个为硝基、氰基或C.sub.1-3烷基羰基，另一个为从硝基、氰基、卤素、C.sub.1-3烷基羰基、甲氧基或氨基中选择的不同基团，该氨基可选地被一个或两个C.sub.1-6烷基或C.sub.2-7酰基取代; R.sub.3和R.sub.4中的任意一个为氢或C.sub.1-4烷基，另一个为C.sub.1-4烷基; 或R.sub.3和R.sub.4共同为C.sub.2-5聚亚甲基; R.sub.5为氢、羟基、C.sub.1-6烷氧基或C.sub.1-7酰氧基; R.sub.6为氢; 或R.sub.5和R.sub.6共同为键合; R.sub.7为氢、C.sub.1-6烷基、C.sub.3-6环烷基、C.sub.2-6烯基或C.sub.2-6炔基; R.sub.8为氢或C.sub.1-6烷基; 或R.sub.7和R.sub.8共同为C.sub.2-4聚亚甲基; R.sub.9为CN、NO.sub.2、COR.sub.10或SO.sub.2R.sub.10，其中R.sub.10为C.sub.1-3烷基、NH.sub.2、NH(C.sub.1-3烷基)、CF.sub.3或苯基，可选地如R.sub.x所定义地取代; 当R.sub.5为羟基、C.sub.1-6烷氧基或C.sub.1-7酰氧基时，R.sub.8N(NR.sub.9)NHR.sub.7基团为与R.sub.5基团相对的构型; 具有降压和/或支气管扩张作用，其制备方法及其作为药物的使用。
• BUCKLE, DEREK R.;ARCH, JONATHAN R. S.;EDGE, COLIN;FOSTER, KEITH A.;HOUGE-+, J. MED. CHEM., 34,(1991) N, C. 919-926
  作者：BUCKLE, DEREK R.、ARCH, JONATHAN R. S.、EDGE, COLIN、FOSTER, KEITH A.、HOUGE-+

  DOI：——

  日期：——
• Benzopyran derivatives with antihypertensive activity
  申请人：BEECHAM GROUP PLC

  公开号：EP0359537B1

  公开（公告）日：1996-06-26